Published in J Neurochem on July 09, 2008
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet (2009) 14.86
The role of the anaphylatoxins in health and disease. Mol Immunol (2009) 2.95
Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol (2009) 1.66
Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Mol Psychiatry (2011) 1.59
The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration. J Neurochem (2008) 1.48
Complement protein C1q-mediated neuroprotection is correlated with regulation of neuronal gene and microRNA expression. J Neurosci (2011) 1.41
Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered? J Neuroinflammation (2014) 1.41
Complement in the brain. Mol Immunol (2011) 1.41
Memory deficits in APP23/Abca1+/- mice correlate with the level of Aβ oligomers. ASN Neuro (2009) 1.17
Microglial C5aR (CD88) expression correlates with amyloid-beta deposition in murine models of Alzheimer's disease. J Neurochem (2010) 1.16
Complement activation in the injured central nervous system: another dual-edged sword? J Neuroinflammation (2012) 1.11
Genome-wide association studies: the key to unlocking neurodegeneration? Nat Neurosci (2010) 1.05
Complement in neuroprotection and neurodegeneration. Trends Mol Med (2010) 1.04
Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease. J Neuroinflammation (2011) 1.02
Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis. Front Cell Neurosci (2014) 1.01
Innate immunity and neuroinflammation. Mediators Inflamm (2013) 0.90
Activation of the immune response is a key feature of aging in mice. Biogerontology (2009) 0.89
The major histocompatibility complex and autism spectrum disorder. Dev Neurobiol (2012) 0.88
Antimicrobial peptides and complement in neonatal hypoxia-ischemia induced brain damage. Front Immunol (2015) 0.83
From development to dysfunction: microglia and the complement cascade in CNS homeostasis. Ageing Res Rev (2013) 0.83
Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's Disease. J Neurosci (2016) 0.82
Molecular signatures of neurodegeneration in the cortex of PS1/PS2 double knockout mice. Mol Neurodegener (2008) 0.82
Panel of Genetic Variations as a Potential Non-invasive Biomarker for Early Diagnosis of Alzheimer's Disease. Clin Psychopharmacol Neurosci (2011) 0.79
Complement activation fragment C5a receptors, CD88 and C5L2, are associated with neurofibrillary pathology. J Neuroinflammation (2013) 0.79
CSF complement 3 and factor H are staging biomarkers in Alzheimer's disease. Acta Neuropathol Commun (2016) 0.78
Investigation of interaction of vaccinia virus complement control protein and curcumin with complement components c3 and c3b using quartz crystal microbalance with dissipation monitoring technology. Open Biochem J (2010) 0.75
C5a Increases the Injury to Primary Neurons Elicited by Fibrillar Amyloid Beta. ASN Neuro (2017) 0.75
Signaling pathways regulating neuron-glia interaction and their implications in Alzheimer's disease. J Neurochem (2015) 0.75
Cell-specific deletion of C1qa identifies microglia as the dominant source of C1q in mouse brain. J Neuroinflammation (2017) 0.75
Fluoride Induces Neuroinflammation and Alters Wnt Signaling Pathway in BV2 Microglial Cells. Inflammation (2017) 0.75
Prevention of C5aR1 signaling delays microglial inflammatory polarization, favors clearance pathways and suppresses cognitive loss. Mol Neurodegener (2017) 0.75
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (1996) 19.72
A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A (2005) 13.44
The classical complement cascade mediates CNS synapse elimination. Cell (2007) 9.06
Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet (2006) 8.33
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet (1998) 8.20
Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med (1998) 5.78
Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet (2007) 4.23
Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol (2002) 3.62
Contributions of the Mac-1 glycoprotein family to adherence-dependent granulocyte functions: structure-function assessments employing subunit-specific monoclonal antibodies. J Immunol (1986) 3.35
Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A (1992) 2.84
Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A (2002) 2.76
The Alzheimer's A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci U S A (2002) 2.74
Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol (1982) 1.93
The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res (2002) 1.85
Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med (1998) 1.84
Complement: a novel factor in basal and ischemia-induced neurogenesis. EMBO J (2006) 1.70
Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J Neurosci (2004) 1.66
Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am J Pathol (2001) 1.66
Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science (1999) 1.65
Opsonization with C1q and mannose-binding lectin targets apoptotic cells to dendritic cells. J Immunol (2004) 1.64
Complement proteins C1q and MBL are pattern recognition molecules that signal immediate and long-term protective immune functions. Mol Immunol (2006) 1.61
Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann N Y Acad Sci (2003) 1.60
Modulation of FcR function by complement: subcomponent C1q enhances the phagocytosis of IgG-opsonized targets by human monocytes and culture-derived macrophages. J Immunol (1987) 1.51
Complement anaphylatoxin receptors on neurons: new tricks for old receptors? Trends Neurosci (1999) 1.41
C1q and MBL, components of the innate immune system, influence monocyte cytokine expression. J Leukoc Biol (2006) 1.40
beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J Immunol (1994) 1.38
Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging (1997) 1.36
Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J (2006) 1.33
Localization and cell association of C1q in Alzheimer's disease brain. Exp Neurol (1996) 1.32
Primary cultures of murine astrocytes produce C3 and factor B, two components of the alternative pathway of complement activation. J Immunol (1987) 1.32
Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays. Mol Immunol (2004) 1.32
Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. J Neuroimmunol (2004) 1.29
Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res (1997) 1.24
Deletion of the complement anaphylatoxin C3a receptor attenuates, whereas ectopic expression of C3a in the brain exacerbates, experimental autoimmune encephalomyelitis. J Immunol (2004) 1.21
Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J Cell Biochem (1999) 1.18
Generation of inhibitory NFkappaB complexes and phosphorylated cAMP response element-binding protein correlates with the anti-inflammatory activity of complement protein C1q in human monocytes. J Biol Chem (2007) 1.15
Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease. Am J Pathol (2000) 1.13
The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol Aging (1997) 1.12
Beta-amyloid accumulation correlates with cognitive dysfunction in the aged canine. Neurobiol Learn Mem (1996) 1.11
Complement gene expression in human brain: comparison between normal and Alzheimer disease cases. Brain Res Mol Brain Res (1992) 1.11
Expression of a complete and functional complement system by human neuronal cells in vitro. Int Immunol (2000) 1.10
Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis. J Neuroinflammation (2004) 1.10
Hereditary deficiencies in complement C5 are associated with intensified neurodegenerative responses that implicate new roles for the C-system in neuronal and astrocytic functions. Neurobiol Dis (1996) 1.10
Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death. Neuroreport (2001) 1.06
Complement component C1q inhibits beta-amyloid- and serum amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms. J Neurochem (2007) 1.06
Effect of graft perfusion with two CD45 monoclonal antibodies on incidence of kidney allograft rejection. Lancet (1989) 1.06
Complement mRNA in the mammalian brain: responses to Alzheimer's disease and experimental brain lesioning. Neurobiol Aging (1993) 1.05
Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J Neurosci (2000) 1.05
Complement activation in chromosome 13 dementias. Similarities with Alzheimer's disease. J Biol Chem (2002) 1.04
The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimer's disease. J Neuroimmunol (2000) 1.03
Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. Adv Drug Deliv Rev (2002) 1.03
Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. J Neuroinflammation (2005) 1.03
Complement C1q regulates LPS-induced cytokine production in bone marrow-derived dendritic cells. Eur J Immunol (2004) 1.02
Selective expression of clusterin (SGP-2) and complement C1qB and C4 during responses to neurotoxins in vivo and in vitro. Neuroscience (1994) 1.02
Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor. Exp Neurol (1999) 1.02
Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. Brain Res Mol Brain Res (2000) 1.01
Cutting edge: C1q protects against the development of glomerulonephritis independently of C3 activation. J Immunol (1999) 1.01
Expression of C5a in the brain does not exacerbate experimental autoimmune encephalomyelitis. Neurosci Lett (2005) 1.00
Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events. Neurobiol Aging (2001) 1.00
Blockade of the C5a receptor fails to protect against experimental autoimmune encephalomyelitis in rats. Clin Exp Immunol (2004) 0.98
Glial fibrillary acidic protein immunoreactivity in normal and diseased human breast. Virchows Arch A Pathol Anat Histopathol (1991) 0.98
Plaque complement activation and cognitive loss in Alzheimer's disease. J Neuroinflammation (2008) 0.97
Induction of C3 expression in astrocytes is regulated by cytokines and Newcastle disease virus. J Immunol (1992) 0.96
C5b-9 complement complex in autoimmune demyelination and multiple sclerosis: dual role in neuroinflammation and neuroprotection. Ann Med (2005) 0.95
Induction of complement proteins in a mouse model for cerebral microvascular A beta deposition. J Neuroinflammation (2007) 0.94
beta-Amyloid converts an acute phase injury response to chronic injury responses. Neurobiol Aging (1997) 0.93
C3a expressed in the central nervous system protects against LPS-induced shock. Neurosci Lett (2005) 0.91
Beta-amyloid precursor protein is detectable on monocytes and is increased in Alzheimer's disease. Neurobiol Aging (2000) 0.91
Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner. Clin Exp Immunol (1999) 0.91
Complement C5a receptor-mediated signaling may be involved in neurodegeneration in Alzheimer's disease. J Immunol (2003) 0.91
An immunohistochemical study on cerebral vascular and senile plaque amyloid in Alzheimer's dementia. Virchows Arch B Cell Pathol Incl Mol Pathol (1984) 0.89
Key issues in Alzheimer's disease inflammation. Neurobiol Aging (2000) 0.88
Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection. J Neuroimmunol (2006) 0.87
Differential regulation of Abeta42-induced neuronal C1q synthesis and microglial activation. J Neuroinflammation (2005) 0.85
Amyloid-beta immunization in Alzheimer's disease transgenic mouse models and wildtype mice. Neurochem Res (2003) 0.84
Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2. Acta Neuropathol (2001) 0.83
Substrate specificities of murine C1s. J Immunol (1994) 0.80
Monoclonal antibodies to complement components without the need of their prior purification. II. Antibodies to mouse C3 and C4. Hybridoma (1990) 0.80
Polymorphonuclear neutrophils release 35S-labelled proteoglycans into cartilage during frustrated phagocytosis. Eur J Biochem (1994) 0.77
The role of the anaphylatoxins in health and disease. Mol Immunol (2009) 2.95
Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J Neurosci (2004) 1.66
Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol (2009) 1.66
Complement proteins C1q and MBL are pattern recognition molecules that signal immediate and long-term protective immune functions. Mol Immunol (2006) 1.61
Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J Neuroinflammation (2012) 1.57
Complement protein C1q directs macrophage polarization and limits inflammasome activity during the uptake of apoptotic cells. J Immunol (2012) 1.57
Complement protein C1q-mediated neuroprotection is correlated with regulation of neuronal gene and microRNA expression. J Neurosci (2011) 1.41
Complement in the brain. Mol Immunol (2011) 1.41
C1q and MBL, components of the innate immune system, influence monocyte cytokine expression. J Leukoc Biol (2006) 1.40
A dramatic increase of C1q protein in the CNS during normal aging. J Neurosci (2013) 1.35
C1q differentially modulates phagocytosis and cytokine responses during ingestion of apoptotic cells by human monocytes, macrophages, and dendritic cells. J Immunol (2009) 1.32
ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem (2006) 1.28
The role of the complement system and the activation fragment C5a in the central nervous system. Neuromolecular Med (2009) 1.27
C1qRp defines a new human stem cell population with hematopoietic and hepatic potential. Proc Natl Acad Sci U S A (2002) 1.26
C1q enhances microglial clearance of apoptotic neurons and neuronal blebs, and modulates subsequent inflammatory cytokine production. J Neurochem (2009) 1.25
Murine low-density lipoprotein receptor-related protein 1 (LRP) is required for phagocytosis of targets bearing LRP ligands but is not required for C1q-triggered enhancement of phagocytosis. J Immunol (2008) 1.20
Microglial C5aR (CD88) expression correlates with amyloid-beta deposition in murine models of Alzheimer's disease. J Neurochem (2010) 1.16
Generation of inhibitory NFkappaB complexes and phosphorylated cAMP response element-binding protein correlates with the anti-inflammatory activity of complement protein C1q in human monocytes. J Biol Chem (2007) 1.15
C1q-induced LRP1B and GPR6 proteins expressed early in Alzheimer disease mouse models, are essential for the C1q-mediated protection against amyloid-β neurotoxicity. J Biol Chem (2012) 1.11
CD93 is rapidly shed from the surface of human myeloid cells and the soluble form is detected in human plasma. J Immunol (2005) 1.08
Complement component C1q inhibits beta-amyloid- and serum amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms. J Neurochem (2007) 1.06
Sialic acid on the neuronal glycocalyx prevents complement C1 binding and complement receptor-3-mediated removal by microglia. J Neurosci (2012) 1.03
Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. J Neuroinflammation (2005) 1.03
Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease. J Neuroinflammation (2011) 1.02
CD93 interacts with the PDZ domain-containing adaptor protein GIPC: implications in the modulation of phagocytosis. J Leukoc Biol (2004) 0.98
The double-edged flower: roles of complement protein C1q in neurodegenerative diseases. Adv Exp Med Biol (2006) 0.96
Innate immune proteins C1q and mannan-binding lectin enhance clearance of atherogenic lipoproteins by human monocytes and macrophages. J Immunol (2010) 0.95
Complement C1q expression induced by Abeta in rat hippocampal organotypic slice cultures. Exp Neurol (2004) 0.92
Neuronal localization of C1q in preclinical Alzheimer's disease. Neurobiol Dis (2004) 0.92
Cell surface expression of C1qRP/CD93 is stabilized by O-glycosylation. J Cell Physiol (2003) 0.90
Complement in BuB/BnJ mice revisited: serum C3 levels and complement opsonic activity are not elevated. Mol Immunol (2005) 0.90
Modulated interaction of the ERM protein, moesin, with CD93. Immunology (2005) 0.87
A novel CD93 polymorphism in non-obese diabetic (NOD) and NZB/W F1 mice is linked to a CD4+ iNKT cell deficient state. Immunogenetics (2010) 0.85
Differential regulation of Abeta42-induced neuronal C1q synthesis and microglial activation. J Neuroinflammation (2005) 0.85
Development of a humanized C1q A chain knock-in mouse: assessment of antibody independent beta-amyloid induced complement activation. Mol Immunol (2008) 0.84
Real-time imaging of Toxoplasma-infected human monocytes under fluidic shear stress reveals rapid translocation of intracellular parasites across endothelial barriers. Cell Microbiol (2013) 0.80
Complement activation fragment C5a receptors, CD88 and C5L2, are associated with neurofibrillary pathology. J Neuroinflammation (2013) 0.79
Human cord blood leukocyte innate immune responses to defense collagens. Pediatr Res (2003) 0.79